An observation of tofacitinib in patients of SAPHO syndrome with nail involvement

An observation of tofacitinib in patients of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome with nail involvement

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025941

Enrollment

Unknown

Registered

2019-09-15

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome

Interventions

Case series:Tofacitinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 or older; 2. In accordance with the diagnostic criteria of SAPHO reported by Kahn in 2003; 3. Nail involvement defined as target nail NAPSI >= 2 and overall NAPSI > 14 - Target nail is defined as the nail with the highest nail score (matrix+bed scores) at baseline. Should more than one nail have the same score, the target nail will be chosen by the investigator.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. With a desire to have children; 3. DMARDs or biological therapy within 3 months before recruitment; 4. Severe cardiac, hepatic, renal dysfunction; 5. Significant abnormalities in hematology, including anemia, thrombocytopenia, leukopenia. 6. Have evidence of active or latent tuberculosis; 7. Any uncontrolled significant medical condition.

Design outcomes

Primary

Measure	Time frame
NAPSI;	—

Countries

China

Contacts

Public ContactChen Li

Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences

casio1981@163.com+86 13810988688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026